San Diego-based Neurocrine Biosciences says that finance chief Paul W. Hawran is retiring. VP Timothy P. Coughlin will take the position in a transfer scheduled for the first quarter of next year. Kevin C. Gorman was named operating chief.
Targanta Therapeutics has named Mark Leuchtenberger as the company's new president and CEO. Leuchtenberger joins Targanta from Therion Biologics, where he was formerly president and CEO.
Dr. Aiping H. Young will take the position of president and CEO of Lorus Therapeutics.
HTG has appointed Dr. William Radany as its new CEO. He replaces Kirk Collamer who will remain with the company as the CFO.
BioBalance announced the resignation of its CEO, Dennis O'Donnell. It is now seeking a new CEO.
Omega Pharma has appointed internal candidate Jan Cassiman as CEO, replacing Marc Coucke.
Cyberkinetics Neurotechnology Systems announced that it has appointed Kurt H. Kruger to the newly-established position of CFO.
Baxter International has appointed Carlos Alonso president of Baxter Latin America.
Anacor Pharmaceuticals has hired Irwin A. Heyman, Ph.D. as the company's vice president of toxicology and Debra Kay Marti as senior director, clinical development.
Curis has added three new members to its Scientific Advisory Board. They are: Stuart A. Aaronson, M.D., Chairman, Department of Oncological Sciences at The Mount Sinai Medical Center in New York City, and the Jane B. and Jack R. Aron Professor of Neoplastic Diseases; Kenneth J. Pienta, M.D., Professor, Internal Medicine and Urology; Director of the Urologic Oncology program at the University of Michigan Comprehensive Cancer Center; Chair, Translational Medicine Committee of the Southwest Oncology Group (SWOG); and George F. Vande Woude, Ph.D., Director, Van Andel Research Institute; formerly with the National Cancer Institute.
Metabasis Therapeutics announced that David F. Hale has been appointed to the additional post of chairman of the board of directors.
Medarex has elected Robert C. Dinerstein and Abhijeet J. Lele to its board.
Vyteris Holdings has named Gregory B. Lawless Ph.D. to its board.
Immune Response added Dr. James Foght to its board of directors.
Singulex has added Mckey Urdea, Ph.D. to the board of directors.
ChondroGene Limited announced today that former Roche Molecular Systems CEO, Dr. Heiner Dreismann, PhD, has joined ChondroGene's board of directors.